JP2012509892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509892A5 JP2012509892A5 JP2011537692A JP2011537692A JP2012509892A5 JP 2012509892 A5 JP2012509892 A5 JP 2012509892A5 JP 2011537692 A JP2011537692 A JP 2011537692A JP 2011537692 A JP2011537692 A JP 2011537692A JP 2012509892 A5 JP2012509892 A5 JP 2012509892A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- acid
- secretagogue
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 230000000580 secretagogue effect Effects 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 7
- 230000002124 endocrine Effects 0.000 claims 5
- 125000004404 heteroalkyl group Chemical group 0.000 claims 5
- 230000000968 intestinal effect Effects 0.000 claims 5
- 239000003613 bile acid Substances 0.000 claims 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 2
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims 2
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 claims 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 claims 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims 2
- 108010007979 Glycocholic Acid Proteins 0.000 claims 2
- 102000018886 Pancreatic Polypeptide Human genes 0.000 claims 2
- 102100029909 Peptide YY Human genes 0.000 claims 2
- 108010088847 Peptide YY Proteins 0.000 claims 2
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 claims 2
- 239000003833 bile salt Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 2
- 229960003964 deoxycholic acid Drugs 0.000 claims 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims 2
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 claims 2
- 230000003278 mimic effect Effects 0.000 claims 2
- 230000003232 mucoadhesive effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 claims 2
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 claims 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 claims 1
- 239000004380 Cholic acid Substances 0.000 claims 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
- 241000792859 Enema Species 0.000 claims 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 claims 1
- 108010035713 Glycodeoxycholic Acid Proteins 0.000 claims 1
- WVULKSPCQVQLCU-UHFFFAOYSA-N Glycodeoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 WVULKSPCQVQLCU-UHFFFAOYSA-N 0.000 claims 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 claims 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 claims 1
- 229920000148 Polycarbophil calcium Polymers 0.000 claims 1
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- JISBOJIHFHAQPL-UHFFFAOYSA-N benzyl 6-methyl-2-oxo-4-thiophen-2-yl-3,4-dihydro-1h-pyrimidine-5-carboxylate Chemical compound N1C(=O)NC(C)=C(C(=O)OCC=2C=CC=CC=2)C1C1=CC=CS1 JISBOJIHFHAQPL-UHFFFAOYSA-N 0.000 claims 1
- 229940093761 bile salts Drugs 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims 1
- 229940099352 cholate Drugs 0.000 claims 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims 1
- 229960002471 cholic acid Drugs 0.000 claims 1
- 235000019416 cholic acid Nutrition 0.000 claims 1
- 125000003716 cholic acid group Chemical group 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940095399 enema Drugs 0.000 claims 1
- 239000007920 enema Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229940099347 glycocholic acid Drugs 0.000 claims 1
- WVULKSPCQVQLCU-BUXLTGKBSA-N glycodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 WVULKSPCQVQLCU-BUXLTGKBSA-N 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 210000003405 ileum Anatomy 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940100243 oleanolic acid Drugs 0.000 claims 1
- 229950005134 polycarbophil Drugs 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 claims 1
- 229940096976 rectal foam Drugs 0.000 claims 1
- 229940041666 rectal gel Drugs 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11832408P | 2008-11-26 | 2008-11-26 | |
| US61/118,324 | 2008-11-26 | ||
| US25521109P | 2009-10-27 | 2009-10-27 | |
| US61/255,211 | 2009-10-27 | ||
| PCT/US2009/065587 WO2010062863A2 (en) | 2008-11-26 | 2009-11-23 | Compositions containing satiogens and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014004971A Division JP2014062134A (ja) | 2008-11-26 | 2014-01-15 | サティオゲン類を含有する組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012509892A JP2012509892A (ja) | 2012-04-26 |
| JP2012509892A5 true JP2012509892A5 (https=) | 2013-01-17 |
Family
ID=41572705
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537692A Pending JP2012509892A (ja) | 2008-11-26 | 2009-11-23 | サティオゲン類を含有する組成物及び使用の方法 |
| JP2014004971A Pending JP2014062134A (ja) | 2008-11-26 | 2014-01-15 | サティオゲン類を含有する組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014004971A Pending JP2014062134A (ja) | 2008-11-26 | 2014-01-15 | サティオゲン類を含有する組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US8318663B2 (https=) |
| EP (1) | EP2364161B1 (https=) |
| JP (2) | JP2012509892A (https=) |
| CN (1) | CN102316889B (https=) |
| CA (1) | CA2744697C (https=) |
| GB (1) | GB2465677B (https=) |
| WO (1) | WO2010062863A2 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8242294B2 (en) | 2007-06-19 | 2012-08-14 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
| JOP20180077A1 (ar) | 2007-06-19 | 2019-01-30 | Kythera Biopharmaceuticals Inc | تركيبات وطرق لحمض صفراوي تخليقي |
| US20080318870A1 (en) | 2007-06-19 | 2008-12-25 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
| CA2744697C (en) | 2008-11-26 | 2016-06-21 | Satiogen Pharmaceuticals, Inc. | Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes |
| WO2010062861A2 (en) * | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
| US9314444B2 (en) | 2009-01-12 | 2016-04-19 | Biokier, Inc. | Composition and method for treatment of NASH |
| KR20110120866A (ko) * | 2009-01-12 | 2011-11-04 | 바이오키어 인코포레이티드 | 당뇨병 치료 조성물 및 치료방법 |
| WO2012151252A2 (en) * | 2011-05-02 | 2012-11-08 | Biokier, Inc. | Composition and method for treatment of diabetes |
| US9006288B2 (en) | 2009-01-12 | 2015-04-14 | Biokier, Inc. | Composition and method for treatment of diabetes |
| US9301938B2 (en) | 2009-09-23 | 2016-04-05 | Biokier, Inc. | Composition and method for treatment of diabetes |
| EP2485738A4 (en) * | 2009-10-09 | 2015-04-01 | Atheronova Operations Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF ADIPOSITAS |
| WO2011075539A2 (en) * | 2009-12-18 | 2011-06-23 | Satiogen Pharmaceuticals, Inc. | Treatment of obesity or diabetes with bile acid sequestrants |
| US20130273154A1 (en) * | 2011-03-02 | 2013-10-17 | Joseph M. Fayad | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes |
| ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
| US9127036B2 (en) | 2010-08-12 | 2015-09-08 | Kythera Biopharmaceuticals, Inc. | Synthetic bile acid compositions and methods |
| EP2739286A4 (en) * | 2011-08-04 | 2015-06-03 | Lumena Pharmaceuticals Inc | GALLENIC ACID FLUID FOR THE TREATMENT OF PANCREATITIS |
| WO2013049595A1 (en) * | 2011-09-29 | 2013-04-04 | Ethicon Endo-Surgery, Inc. | Methods and compositions of bile acids |
| US20130108573A1 (en) | 2011-10-28 | 2013-05-02 | Lumena Pharmaceuticals, Inc. | Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease |
| AU2012328526B2 (en) | 2011-10-28 | 2017-05-25 | Shire Human Genetic Therapies, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| US9402968B2 (en) | 2012-07-11 | 2016-08-02 | Mercy Medical Research Institute, Inc. | Colorectal delivery device |
| CN104644591A (zh) * | 2013-11-25 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 一种沙格列汀药物组合物及其制备方法 |
| DK3082466T3 (da) * | 2013-12-18 | 2019-10-07 | Thylabisco Ab | Anvendelse af thylakoider til formindskelse af trangen til velsmagende næringsmidler |
| KR101812530B1 (ko) * | 2014-02-12 | 2017-12-27 | 야마하하쓰도키 가부시키가이샤 | 촬영 장치, 차량 및 화상 보정 방법 |
| JP7164950B2 (ja) * | 2014-10-31 | 2022-11-02 | ユニバーシティー オブ ユタ リサーチ ファウンデーション | 胆汁酸粒子の組成物及び方法 |
| EP3115037B1 (de) * | 2015-07-08 | 2018-08-15 | Dr. Falk Pharma Gmbh | Pharmazeutische formulierung zur behandlung von entzündlichen veränderungen des enddarms |
| JPWO2017170858A1 (ja) * | 2016-03-31 | 2019-02-14 | インターセプト ファーマシューティカルズ， インコーポレイテッド | 溶出性に優れた経口製剤 |
| CA3019499A1 (en) * | 2016-03-31 | 2017-10-05 | Intercept Pharmaceuticals, Inc. | Film-coated tablet having high chemical stability of active ingredient |
| US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
| US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
| US12186329B2 (en) | 2018-08-23 | 2025-01-07 | President And Fellows Of Harvard College | Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes |
| EP3890745B1 (en) | 2018-12-04 | 2025-11-19 | President and Fellows of Harvard College | Synthetic derivatives of cholic acid 7-sulfate and uses thereof |
| JP2020186223A (ja) * | 2019-05-09 | 2020-11-19 | 救心製薬株式会社 | 牛黄及び／又は鹿茸及び／又は胆汁酸を含有する組成物 |
| KR20250171471A (ko) | 2019-05-10 | 2025-12-08 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 장 박테리아 담즙산 대사의 소분자 조정제 |
| CN110314167A (zh) * | 2019-07-04 | 2019-10-11 | 北京大学第三医院（北京大学第三临床医学院） | 胆汁酸作为制备治疗pcos药物的应用及药物制剂 |
| JP2022544239A (ja) | 2019-08-12 | 2022-10-17 | マサチューセッツ インスティテュート オブ テクノロジー | 治療薬の投与のための物品及び方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA876930B (en) * | 1986-10-07 | 1988-05-25 | Hoffmann La Roche | Pharmaceutical compositions |
| IT1245890B (it) | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari. |
| US5415872A (en) * | 1992-06-22 | 1995-05-16 | Digestive Care Inc. | Compositions of gastric acid-resistant microspheres containing salts of bile acids |
| US5330761A (en) * | 1993-01-29 | 1994-07-19 | Edward Mendell Co. Inc. | Bioadhesive tablet for non-systemic use products |
| KR970005178B1 (ko) | 1993-12-28 | 1997-04-14 | 이승철 | 피로회복제 조성물 |
| DE122010000020I1 (de) * | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| US5908830A (en) * | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
| US6060465A (en) * | 1997-02-06 | 2000-05-09 | Miljkovic; Dusan | Bile acids and their derivatives as glycoregulatory agents |
| EP2583675A1 (en) * | 1998-02-02 | 2013-04-24 | Trustees Of Tufts College | Use of dipeptidylpeptidase inhibitors to regulate glucose metabolism |
| JP2000026300A (ja) | 1998-07-02 | 2000-01-25 | Pola Chem Ind Inc | 血管内皮細胞保護医薬組成物 |
| SE9901387D0 (sv) | 1999-04-19 | 1999-04-19 | Astra Ab | New pharmaceutical foromaulations |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| EP1743655B1 (en) * | 2000-01-21 | 2014-06-25 | Novartis AG | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| CA2401290A1 (en) | 2000-04-12 | 2001-10-18 | Takeda Chemical Industries, Ltd. | Novel g protein-coupled receptor protein and dna thereof |
| US6451355B1 (en) * | 2000-07-17 | 2002-09-17 | Howard M. Reisner | Composition to treat diabetes |
| US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| US7198914B2 (en) | 2000-11-17 | 2007-04-03 | Banyu Pharmaceutical Co., Ltd. | Guanosine triphosphate (GTP)-binding protein-coupled receptor protein, BG37 |
| MXPA04011584A (es) * | 2002-05-23 | 2005-03-31 | Umd Inc | Composiciones y metodo para la administracion y crioproteccion de drogas transmucosales. |
| US7312208B2 (en) * | 2002-08-28 | 2007-12-25 | Asahi Kasei Pharma Corporation | Quaternary ammonium compounds |
| US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
| JP2005097216A (ja) * | 2003-09-26 | 2005-04-14 | Kaneka Corp | ＰＰＡＲγリガンド剤 |
| EP1799263A4 (en) * | 2004-09-15 | 2009-07-29 | Harvard College | REDUCTION OF ER-STRESS IN THE TREATMENT OF ADIPOSITAS AND DIABETES |
| EP1819318A1 (en) | 2004-11-24 | 2007-08-22 | Seo Hong Yoo | Dried forms of aqueous solubilized bile acid dosage formulation |
| US20060193895A1 (en) * | 2005-02-25 | 2006-08-31 | Use-Techno Corporation | Additive for food and beverage, pharmaceutical composition, GLUT4 translocator, and method for translocating GLUT4 |
| FR2883284A1 (fr) | 2005-03-15 | 2006-09-22 | Commissariat Energie Atomique | Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux |
| US20080031968A1 (en) * | 2005-04-01 | 2008-02-07 | The Brigham And Women's Hospital, Inc. | Methods for increasing cellular energy expenditure |
| WO2006116814A1 (en) | 2005-05-02 | 2006-11-09 | Vanadis Bioscience Ltd | Composition and uses thereof |
| JP2010517931A (ja) | 2006-02-14 | 2010-05-27 | インターセプト ファーマシューティカルズ， インコーポレイテッド | Ｆｘｒ媒介性の疾患または状態の予防または治療用のｆｘｒリガンドとしての胆汁酸誘導体 |
| PE20080251A1 (es) * | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| PT2040713E (pt) | 2006-06-27 | 2014-10-13 | Intercept Pharmaceuticals Inc | Para a prevenção ou o tratamento de doenças ou estados clínicos mediados por fxr |
| DE502007006208D1 (de) | 2006-11-14 | 2011-02-17 | Sanofi Aventis Deutschland | Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2008067219A2 (en) | 2006-11-29 | 2008-06-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
| AU2008209566C1 (en) | 2007-01-19 | 2013-02-14 | Intercept Pharmaceuticals, Inc. | 23-substituted bile acids as TGR5 modulators and methods of use thereof |
| US20080221161A1 (en) * | 2007-02-09 | 2008-09-11 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| ES2663948T3 (es) | 2008-11-19 | 2018-04-17 | Intercept Pharmaceuticals, Inc. | Moduladores de TGR5 y método de uso de los mismos |
| CA2744697C (en) | 2008-11-26 | 2016-06-21 | Satiogen Pharmaceuticals, Inc. | Use of compositions comprising bile acids, salts, and mimics thereof for the treatment of obesity or diabetes |
| KR20110120866A (ko) | 2009-01-12 | 2011-11-04 | 바이오키어 인코포레이티드 | 당뇨병 치료 조성물 및 치료방법 |
| US9301938B2 (en) | 2009-09-23 | 2016-04-05 | Biokier, Inc. | Composition and method for treatment of diabetes |
-
2009
- 2009-11-23 CA CA2744697A patent/CA2744697C/en active Active
- 2009-11-23 US US12/624,345 patent/US8318663B2/en active Active
- 2009-11-23 CN CN200980155866.7A patent/CN102316889B/zh not_active Expired - Fee Related
- 2009-11-23 JP JP2011537692A patent/JP2012509892A/ja active Pending
- 2009-11-23 EP EP09829741.9A patent/EP2364161B1/en active Active
- 2009-11-23 WO PCT/US2009/065587 patent/WO2010062863A2/en not_active Ceased
- 2009-11-26 GB GB0920703.6A patent/GB2465677B/en not_active Expired - Fee Related
-
2012
- 2012-11-09 US US13/673,820 patent/US9345715B2/en active Active
-
2014
- 2014-01-15 JP JP2014004971A patent/JP2014062134A/ja active Pending
-
2016
- 2016-04-22 US US15/136,539 patent/US10028952B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012509892A5 (https=) | ||
| US11440889B2 (en) | Analogs of fexaramine and methods of making and using | |
| EP3419623B1 (en) | Methods for using fxr agonists | |
| AU2017223155B2 (en) | Methods for using FXR agonists | |
| US12329823B2 (en) | Long-acting dual GIP/GLP-1 peptide conjugates and methods of use | |
| JP2005511636A5 (https=) | ||
| JP2020040979A (ja) | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 | |
| RU2017112738A (ru) | Фармацевтические композиции, содержащие варианты пептидов, и способы их применения | |
| JP2023504184A (ja) | ペプチドコンジュゲートおよび使用方法 | |
| US20160376279A1 (en) | Fxr agonists and methods for making and using | |
| EA017714B1 (ru) | Модуляторы tgr5 и способы их применения | |
| JP2017533194A5 (https=) | ||
| RU2014117678A (ru) | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью | |
| EP3419624A1 (en) | Methods for using fxr agonists | |
| WO2015138969A1 (en) | Analogs of fexaramine and methods of making and using | |
| WO2013090454A3 (en) | Carboxylic acid derivatives comprising four cycles acting as glp-1 receptor modulators for therapy of diseases such as diabetes | |
| JP2019520329A5 (https=) | ||
| JP2012504619A5 (https=) | ||
| WO2017078928A1 (en) | Fxr agonists and methods for making and using | |
| US12419897B2 (en) | Synthetic derivatives of cholic acid 7-sulfate and uses thereof | |
| JP2021519763A5 (https=) | ||
| AU2016233579A1 (en) | Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors | |
| CA3073011C (en) | Acylated oxyntomodulin peptide analog | |
| JP2002526530A (ja) | 置換された１，３−ジアリール−２−ピリド−２−イル−３−（ピリド−２−イルアミノ）プロパノール誘導体、その製造方法、それを含有する医薬およびその使用 | |
| WO2014117292A1 (zh) | 酰胺类化合物及其制备方法、药物组合物和用途 |